Abstract

Case Report

Urinary Biomarkers: Is the Era of Exclusive Follow-Up Cystoscopy Coming to an End? A Mini-Review of Emerging Molecular Diagnostics and Risk-Stratified Surveillance

Mohammed Amine Elafari, Mamad Ayoub, Mohammed Amine Bibat, Amine Slaoui, Tariq Karmouni, Abdelatif Koutani and Khalid Elkhader

Published: 08 April, 2026 | Volume 10 - Issue 1 | Pages: 011-015

Bladder cancer is among the most costly malignancies to treat, primarily due to the high rate of recurrence for Non-Muscle-Invasive Bladder Cancer (NMIBC) and the subsequent necessity for lifelong cystoscopic surveillance. Although cystoscopy is widely regarded as the gold standard, it is an invasive procedure that can be costly and is associated with patient discomfort and anxiety. In recent years, a novel generation of urinary biomarkers (comprising genomic, epigenomic, and proteomic assays) has emerged, exhibiting diagnostic capabilities that increasingly challenge the prevailing role of cystoscopy in surveillance protocols. This mini-review examines the landscape of FDA-approved and emerging urinary biomarkers, compares their diagnostic accuracy, evaluates the first randomized controlled trials supporting biomarker-guided surveillance, and proposes a risk-stratified algorithm for the future integration of urinary biomarkers into clinical practice.

Read Full Article HTML DOI: 10.29328/journal.acst.1001050 Cite this Article Read Full Article PDF

Keywords:

Bladder cancer; Non-Muscle Invasive Bladder Cancer (NMIBC); Urinary biomarkers; Molecular diagnostics; Cystoscopy; Urine cytology; Cancer surveillance; Cancer recurrence; Urothelial carcinoma; Genomic biomarkers

References

  1. Yang Z, Song F, Zhong J. Urinary biomarkers in bladder cancer: FDA-approved tests and emerging tools for diagnosis and surveillance. Cancers. 2025;17(21):3425. Available from: https://pubmed.ncbi.nlm.nih.gov/41228219/
  2. Hsia Y, Chiang C, Chiang C, Chiang C, Wang S, Chang Y, et al. Clinical performance of Bladder EpiCheck methylation test for active surveillance of non-muscle invasive bladder cancer: systematic review and meta-analysis. J Clin Oncol. 2023;41(Suppl 16):e16597. Available from: https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e16597
  3. National Comprehensive Cancer Network. Bladder cancer. 2026. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417
  4. Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533-538. Available from: https://pubmed.ncbi.nlm.nih.gov/38265030/
  5. Vedeld HM, Pharo H, Sørbø AK, Brandt-Winge S, Five M, Jeanmougin M, et al. Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer. Mol Oncol. 2024;18(11):2684-2695. Available from: https://pubmed.ncbi.nlm.nih.gov/38720532/
  6. Ecke TH, Meisl CJ, Schlomm T, Rabien A. Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in comparison to cytology. Urology. 2025;197:119-125. Available from: https://www.researchgate.net/publication/386319602_Performance_of_urinary_markers_in_patients_with_suspicious_cystoscopy_during_follow-up_of_recurrent_non-muscle_invasive_bladder_cancer_BTA_statR_NMP22R_BladderChekR_UBCR_Rapid_Test_CancerCheckR_UBCR_r
  7. Lotan Y, O’Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017;35(8):531.e15-531.e22. Available from: https://pubmed.ncbi.nlm.nih.gov/28366272/
  8. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. 2015;163(12):922-31. Available from: https://pubmed.ncbi.nlm.nih.gov/26501851/
  9. Todenhöfer T, Hennenlotter J, Esser M, Mohrhardt S, Aufderklamm S, Böttge J, et al. Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer. Dis Markers. 2014;2014:973406. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4284969/
  10. Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, et al. Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. J Urol. 2017;197(6):1419-1426. Available from: https://pubmed.ncbi.nlm.nih.gov/27986532/
  11. Lotan Y, Daneshmand S, Shore N, Black P, Scarpato KR, Patel A, et al. A multicenter prospective randomized controlled trial comparing Cxbladder triage to cystoscopy in patients with microhematuria: the safe testing of risk for asymptomatic microhematuria trial. J Urol. 2024;212(1):41-51. Available from: https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000003991
  12. Pichler R, Fritz J, Tulchiner G, Klinglmair G, Soleiman A, Horninger W, et al. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. BJU Int. 2018;121(1):29-37. Available from: https://pubmed.ncbi.nlm.nih.gov/28941000/
  13. Dreyer T, Brandt S, Fabrin K, Azawi N, Vásquez JL, Ernst A, et al. Use of the Xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial. Eur Urol. 2025;88(1):23-30. Available from: https://www.sciencedirect.com/science/article/pii/S0302283825001915
  14. Kravchuk AP, Wolff I, Gilfrich C, Wirtz RM, Soares P, Braun K, et al. Urine-based biomarker test Uromonitor® in the detection and disease monitoring of non-muscle-invasive bladder cancer - a systematic review and meta-analysis of diagnostic test performance. Cancers. 2024;16(4):753. Available from: https://pubmed.ncbi.nlm.nih.gov/38398144/
  15. Siguencia F, Heard J, Smith SM, Pagano I, Furuya H, Wu X, et al. Diagnostic performance of urinary biomarker tests in detecting bladder cancer: a systematic review, meta-analysis, and network meta-analysis. Urology. 2026;199:S0090-4295(26)00074-9. Available from: https://pubmed.ncbi.nlm.nih.gov/41651230/
  16. Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—a summary of the 2024 guidelines update. Eur Urol. 2024;86(6):531-549. Available from: https://www.sciencedirect.com/science/article/pii/S0302283824025144
  17. Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712-1721. Available from: https://pubmed.ncbi.nlm.nih.gov/36174585/
  18. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EV, Escrig JLD, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94. Available from: https://pubmed.ncbi.nlm.nih.gov/34511303/
  19. Soorojebally Y, Neuzillet Y, Roumiguié M, Lamy PJ, Allory Y, Descotes F, et al. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review. World J Urol. 2023;41(2):345-359. Available from: https://pubmed.ncbi.nlm.nih.gov/36592175/
  20. Guo X, He L, Yang K, Han H, Wei Y, Gong Y, et al. Clinical effectiveness of urine DNA for minimal residual disease (MRD) monitoring of urothelial carcinoma in urine: a multicenter, prospective, observational study. J Clin Oncol. 2025;43(Suppl 16):TPS4617. Available from: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4617

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?